Turnstone Biologics (TSBX) Stock Price, News & Analysis

-0.07 (-2.56%)
(As of 05/17/2024 08:54 PM ET)
Today's Range
50-Day Range
52-Week Range
109,500 shs
Average Volume
170,958 shs
Market Capitalization
$61.53 million
P/E Ratio
Dividend Yield
Price Target

Turnstone Biologics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.50 Rating Score
614.3% Upside
$19.00 Price Target
Short Interest
5.22% of Float Sold Short
Dividend Strength
News Sentiment
-0.78mentions of Turnstone Biologics in the last 14 days
Based on 4 Articles This Week
Insider Trading
Proj. Earnings Growth
From ($3.34) to ($3.22) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.10 out of 5 stars

Medical Sector

586th out of 914 stocks

Biological Products, Except Diagnostic Industry

95th out of 153 stocks

TSBX stock logo

About Turnstone Biologics Stock (NASDAQ:TSBX)

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, head and neck cancer and uveal melanoma, as well as an investigator sponsored trials to treat colorectal cancer, head and neck cancer, and cutaneous and non-cutaneous melanomas. It is also developing TIDAL-02, which is in preclinical development for the treatment of solid tumors. The company was founded in 2014 and is based in LA Jolla, California.

TSBX Stock Price History

TSBX Stock News Headlines

Turnstone Biologics Corp. (TSBX)
TSBX Turnstone Biologics Corp.
RUM, ENVB and GAME among mid-day movers
IPOs In 2023 Disappoint But 2024 Looks Brighter
Turnstone Biologics price target lowered to $15 from $18 at BofA
Turnstone Biologics GAAP EPS of -$1.00
Turnstone Biologics GAAP EPS of $1.00
Turnstone Biologics Corp TSBX
See More Headlines
Receive TSBX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Turnstone Biologics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Industry, Sector and Symbol

Biological products, except diagnostic
Current Symbol
Year Founded

Price Target and Rating

Average Stock Price Target
High Stock Price Target
Low Stock Price Target
Potential Upside/Downside
Consensus Rating
Moderate Buy
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
$19.31 million
Book Value
$4.27 per share


Free Float
Market Cap
$61.53 million
Not Optionable
Beginner's Guide to Pot Stock Investing Cover

Click the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise.

Get This Free Report

Key Executives

  • Dr. Sammy J. Farah M.B.A. (Age 52)
    Ph.D., President, CEO & Director
    Comp: $678.51k
  • Dr. Venkat Ramanan Ph.D. (Age 55)
    Chief Financial Officer
    Comp: $346.13k
  • Dr. Michael F. Burgess M.D. (Age 60)
    MBChB, Ph.D., Interim Chief Medical Officer & Executive Director
    Comp: $212.69k
  • Ms. Saryah Azmat (Age 35)
    Chief Business Officer
    Comp: $479.73k
  • Dr. Vijay Chiruvolu M.B.A. (Age 62)
    Ph.D., Interim Chief Technology Officer
  • Dr. Stewart Abbot Ph.D. (Age 57)
    Chief Scientific Officer

TSBX Stock Analysis - Frequently Asked Questions

Should I buy or sell Turnstone Biologics stock right now?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Turnstone Biologics in the last twelve months. There are currently 2 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" TSBX shares.
View TSBX analyst ratings
or view top-rated stocks.

What is Turnstone Biologics' stock price target for 2024?

4 Wall Street analysts have issued 1 year target prices for Turnstone Biologics' shares. Their TSBX share price targets range from $18.00 to $20.00. On average, they anticipate the company's share price to reach $19.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for TSBX
or view top-rated stocks among Wall Street analysts.

How have TSBX shares performed in 2024?

Turnstone Biologics' stock was trading at $2.55 at the beginning of 2024. Since then, TSBX shares have increased by 4.3% and is now trading at $2.66.
View the best growth stocks for 2024 here

When is Turnstone Biologics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, September 6th 2024.
View our TSBX earnings forecast

How were Turnstone Biologics' earnings last quarter?

Turnstone Biologics Corp. (NASDAQ:TSBX) posted its earnings results on Thursday, March, 21st. The company reported ($0.73) EPS for the quarter, topping analysts' consensus estimates of ($0.86) by $0.13.

When did Turnstone Biologics IPO?

Turnstone Biologics (TSBX) raised $80 million in an initial public offering on Friday, July 21st 2023. The company issued 6,666,667 shares at $12.00 per share.

Who are Turnstone Biologics' major shareholders?

Turnstone Biologics' stock is owned by many different institutional and retail investors. Top institutional shareholders include Zimmer Partners LP (0.77%) and Kathleen S. Wright Associates Inc. (0.18%). Insiders that own company stock include Rishi Gupta and Versant Ventures V, Llc.
View institutional ownership trends

How do I buy shares of Turnstone Biologics?

Shares of TSBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:TSBX) was last updated on 5/20/2024 by Staff

From Our Partners